表紙
市場調査レポート

肺癌手術市場(医療機器と治療の見通し)-動向と課題:2010年-2015年

Global Lung Cancer Surgery Market (Devices & Treatment Outlook) - Trends & Challenges (2010 - 2015)

発行 MarketsandMarkets 商品コード 203877
出版日 ページ情報 英文 228 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
肺癌手術市場(医療機器と治療の見通し)-動向と課題:2010年-2015年 Global Lung Cancer Surgery Market (Devices & Treatment Outlook) - Trends & Challenges (2010 - 2015)
出版日: 2011年07月11日 ページ情報: 英文 228 Pages
概要

肺癌は世界中で最も多い癌です。WHOによれば、喫煙の普及などにより発展途上国での肺癌が増加すると見込まれております。世界の2008年の罹患件数は1,608,055件でそのうち55%を発展途上国が占め、今後も罹患件数は増加していく見込みとなっております。

当レポートでは、肺癌手術の種類別、製品別、地域別に各下位市場の動向や見通しについてまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

  • 主なポイント
  • レポートの説明
  • 対象市場
  • 利害関係者
  • 調査方法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主な調査結果
  • 提案

第3章 市場概要

  • イントロダクション
  • 市場の定義
  • 差し迫った課題
  • 市場動向
  • 勝利の法則
  • アンメットニーズ/ギャップ
  • 償還シナリオ
  • 市場のダイナミクス
  • 促進因子と抑制因子
  • 課題
  • 技術の概要
  • エンドユーザー分析
  • 主要企業の市場シェア
  • 今後の動向:パイプライン

第4章 手術種類別肺手術市場

  • イントロダクション
  • 開胸術
  • 低侵襲法

第5章 製品別肺癌手術市場

  • イントロダクション
  • 手術機器
  • 監視/可視化システム
  • 内視鏡下手術

第6章 地域分析

  • 北米
  • 欧州
  • その他の世界の諸国

第7章 競合状況

第8章 企業プロファイル

  • ACCURAY INC.
  • ANGIODYNAMICS
  • BSD MEDICAL CORP
  • COVIDIEN
  • ETHICON ENDO-SURGERY INC.
  • NEOMEND INC.
  • OLYMPUS CORP
  • RICHARD WOLF GMBH
  • SIEMENS HEALTHCARE
  • その他
目次
Product Code: PH 1253

Lung cancer is the most common type of cancer across the globe. According to WHO, lung cancer is expected to be more prominent in the underdeveloped world due to an increase in the use of tobacco products; tobacco is the primary cause of around 80% of all lung cancers. Global incidence of lung cancer was 1,608,055 in 2008 with the developing countries accounting for a major share (55%); 1,694,277 new cases were recorded in 2010 with 1,934,467, 2,213,561, and 2,530,820 as the predicted new cases for the years 2015, 2020, and 2025 respectively.

The lung cancer surgery market is expected to grow at a CAGR of 4.9% during the study period (2010-2015). Thoracotomy is the most widely used surgical procedure for lung cancer treatment accounting for about 74% of all surgical interventions. The market for lung cancer surgeries was valued at $36 billion in 2010 and is expected to grow to $45 billion by 2015. Rising incidence of non-small cell lung cancer globally is the major growth driver for the lung cancer surgery market. Europe accounted for the highest number (40%) of lung cancer surgeries performed in 2010.

Scope of the report

This research report categorizes the lung cancer surgery market on the basis of types of lung cancer surgery procedures, by products, and geography; forecasting revenues and analyzing trends in each of the following submarkets:

On the basis of types of surgeries:

  • Thoracotomy, minimally invasive procedures like video assisted surgery and robotic surgery

On the basis of products:

  • Surgical devices, monitoring & visualizing systems and endosurgical equipments

On the basis of geography:

  • North America, Europe, Rest of the World (ROW)

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 19 company profiles covering all the sub-segments.

What makes our reports unique?

  • We provide the longest market segmentation chain in this industry.
  • We provide 10% customization. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
  • We conduct detailed market positioning, product positioning, and competitive positioning. Entry strategies, gaps, and opportunities are identified for all the stakeholders.
  • Comprehensive market analysis for the following sectors:

Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

  • Which are the high-growth segments/cash cows and how is the market segmented in terms of applications and materials?
  • What are market estimates and forecasts; which markets are doing well and which are not?
  • Where are the gaps and opportunities; what is driving the market?
  • Which are the key playing fields? Which are the winning edge imperatives?
  • How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

Table of Contents

1. INTRODUCTION

  • 1.1. KEY TAKE-AWAYS
  • 1.2. REPORT DESCRIPTION
  • 1.3. MARKETS COVERED
  • 1.4. STAKEHOLDERS
  • 1.5. RESEARCH METHODOLOGY
    • 1.5.1. MARKET SIZE
    • 1.5.2. KEY DATA POINTS FROM SECONDARY SOURCES
    • 1.5.3. KEY DATA POINTS FROM PRIMARY SOURCES
    • 1.5.4. ASSUMPTIONS MADE FOR THE REPORT

2. EXECUTIVE SUMMARY

  • 2.1. OVERVIEW OF THE MARKET
  • 2.2. KEY FINDINGS
  • 2.3. RECOMMENDATIONS
    • 2.3.1. DEVICE: ENDOSCOPES
      • 2.3.1.1. Need for an assistant during surgery to handle the endoscope
        • 2.3.1.1.1. Recommendation - head mounted display with motor sensors
      • 2.3.1.2. Paradox view
        • 2.3.1.2.1. Recommendation - use of diverter swich
    • 2.3.2. PROCESS: NUMBER & SIZE OF INCISIONS
      • 2.3.2.1. 3 to 4 access ports for performing VATS surgery
        • 2.3.2.1.1. Recommendation - Natural Orifice Transesophageal Endoscopic Surgery (NOTES)
    • 2.3.3. DEVICE: SURGICAL STAPLERS & CUTTERS (SURGICAL DEVICES)
      • 2.3.3.1. Compression of intercostal nerves during surgery
        • 2.3.3.1.1. Recommendation - Light weight surgical devices
    • 2.3.3.2. Restricted maneuverability
      • 2.3.3.2.1. Recommendation - Flexible devices
    • 2.3.4. COMBINATION THERAPY

3. MARKET OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. MARKET DEFINITION
    • 3.2.1. LUNG CANCER SURGERY MARKET
    • 3.2.2. FUTURE OF LUNG CANCER SURGERY MARKET
    • 3.2.3. LUNG CANCER SURGERY PRODUCT MARKET
  • 3.3. BURNING ISSUES
    • 3.3.1. SURVIVAL ON A SINGLE LUNG DURING SURGERY
    • 3.3.2. ATRIAL FIBRILLATION & ATRIAL FLUTTER
    • 3.3.3. PULMONARY ARTERIAL HYPERTENSION
    • 3.3.4. THROMBOEMBOLISM
  • 3.4. MARKET TRENDS
    • 3.4.1. VATS
    • 3.4.2. ROBOTIC SURGERY
    • 3.4.3. STEREOTACTIC RADIATION THERAPY
      • 3.4.3.1. CyberKnife system
  • 3.5. WINNING IMPERATIVES
    • 3.5.1. EARLY DIAGNOSIS
      • 3.5.1.1. Using PET scan, MRI scan, CT scan & radiopharmaceuticals
    • 3.5.2. POWERED SURGICAL DEVICES
      • 3.5.2.1. Enhanced precision of surgical lasers, cutting instruments, electrosurgery devices
    • 3.5.3. VATS
      • 3.5.3.1. Thoracoscopes and other surgical equipment related to minimally invasive lung surgery
  • 3.6. UNMET NEEDS/GAPS
    • 3.6.1. EARLY DIAGNOSIS
    • 3.6.2. RELAPSE OF LUNG CANCER AFTER SURGICAL RESECTION
  • 3.7. REIMBURSEMENT SCENARIO
    • 3.7.1. U.S.
    • 3.7.2. CANADA
    • 3.7.3. UK
    • 3.7.4. GERMANY
    • 3.7.5. FRANCE
    • 3.7.6. ITALY
    • 3.7.7. SPAIN
  • 3.8. MARKET DYNAMICS
    • 3.8.1. DRIVERS & RESTRAINTS
      • 3.8.1.1. Increasing number of people undergoing surgical interventions
      • 3.8.1.2. Favorable reimbursement scenario in the developed countries favors the market for lung cancer surgery
      • 3.8.1.3. Innovations in diagnosis and alternate treatment therapies hinder the surgery market for lung cancer
    • 3.8.2. CHALLENGES
      • 3.8.2.1. Surgeons
        • 3.8.2.1.1. Air leaks
        • 3.8.2.1.2. Inoperable tumors due to size/location
        • 3.8.2.1.3. Movement of tumors due to breathing during surgery
      • 3.8.2.2. Patients & caregivers
        • 3.8.2.2.1. Accumulation of fluids in chest
        • 3.8.2.2.2. Shortness of breath
        • 3.8.2.2.3. Pain due to surgery
        • 3.8.2.2.4. Bleeding
    • 3.8.3. TECHNOLOGY OVERVIEW
    • 3.8.4. END-USER ANALYSIS
    • 3.8.5. MARKET SHARE OF MAJOR PLAYERS
    • 3.8.6. FUTURE TRENDS: PIPELINE PROCEDURES

4. LUNG SURGERY MARKET, BY TYPES

  • 4.1. INTRODUCTION
  • 4.2. THORACOTOMY
  • 4.3. MINIMALLY INVASIVE PROCEDURES
    • 4.3.1. VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS)
    • 4.3.2. ROBOTIC SURGERY
    • 4.3.3. OTHERS
      • 4.3.3.1. Endobronchial electrosurgery
      • 4.3.3.2. Percutaneous transcatheter surgery
        • 4.3.3.2.1. Radiofrequency ablation
        • 4.3.3.2.2. Microwave ablation
        • 4.3.3.2.3. Cryoablation

5. LUNG CANCER SURGERY MARKET, BY PRODUCTS

  • 5.1. INTRODUCTION
  • 5.2. SURGICAL DEVICES
    • 5.2.1. HAND INSTRUMENTS
    • 5.2.2. POWERED SURGICAL INSTRUMENTS
      • 5.2.2.1. Lasers
      • 5.2.2.2. Electrosurgical and auxiliary equipment
  • 5.3. MONITORING & VISUALIZING SYSTEMS
    • 5.3.1. CAMERAS & VIDEO SUPPORT
    • 5.3.2. ENDOSCOPIC TROCARS WITH OPTICAL VIEW
  • 5.4. ENDOSURGICAL EQUIPMENT
    • 5.4.1. ENDOSCOPE
    • 5.4.2. MEDICAL ROBOTICS
      • 5.4.2.1. Surgical robots
      • 5.4.2.2. Digital operating rooms
      • 5.4.2.3. Surgical navigation systems

6. GEOGRAPHIC ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. U.S.
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. UK
    • 6.2.2. FRANCE
    • 6.2.3. ITALY
    • 6.2.4. SPAIN
    • 6.2.5. GERMANY
    • 6.2.6. REST OF EUROPE
  • 6.3. REST OF THE WORLD

7. COMPETITIVE LANDSCAPE

8. COMPANY PROFILES

  • 8.1. ACCURAY INC.
    • 8.1.1. OVERVIEW
    • 8.1.2. FINANCIALS
    • 8.1.3. PRODUCTS & SERVICES
    • 8.1.4. STRATEGY
    • 8.1.5. DEVELOPMENTS
  • 8.2. ANGIODYNAMICS
    • 8.2.1. OVERVIEW
    • 8.2.2. FINANCIALS
    • 8.2.3. PRODUCTS & SERVICES
    • 8.2.4. STRATEGY
    • 8.2.5. DEVELOPMENTS
  • 8.3. BSD MEDICAL CORP
    • 8.3.1. OVERVIEW
    • 8.3.2. FINANCIALS
    • 8.3.3. PRODUCTS & SERVICES
    • 8.3.4. STRATEGY
    • 8.3.5. DEVELOPMENTS
  • 8.4. COVIDIEN
    • 8.4.1. OVERVIEW
    • 8.4.2. FINANCIALS
    • 8.4.3. PRODUCTS & SERVICES
    • 8.4.4. STRATEGY
    • 8.4.5. DEVELOPMENTS
  • 8.5. ETHICON ENDO-SURGERY INC.
    • 8.5.1. OVERVIEW
    • 8.5.2. FINANCIALS
    • 8.5.3. PRODUCTS & SERVICES
    • 8.5.4. STRATEGY
    • 8.5.5. DEVELOPMENTS
  • 8.6. NEOMEND INC.
    • 8.6.1. OVERVIEW
    • 8.6.2. FINANCIALS
    • 8.6.3. PRODUCTS & SERVICES
    • 8.6.4. STRATEGY
    • 8.6.5. DEVELOPMENTS
  • 8.7. OLYMPUS CORP
    • 8.7.1. OVERVIEW
    • 8.7.2. FINANCIALS
    • 8.7.3. PRODUCTS & SERVICES
    • 8.7.4. STRATEGY
    • 8.7.5. DEVELOPMENTS
  • 8.8. RICHARD WOLF GMBH
    • 8.8.1. OVERVIEW
    • 8.8.2. PRODUCTS & SERVICES
    • 8.8.3. STRATEGY
    • 8.8.4. DEVELOPMENTS
  • 8.9. SIEMENS HEALTHCARE
    • 8.9.1. OVERVIEW
    • 8.9.2. FINANCIALS
    • 8.9.3. PRODUCTS & SERVICES
    • 8.9.4. STRATEGY
    • 8.9.5. DEVELOPMENTS
  • 8.10. OTHERS
    • 8.10.1. ACKERMANN INSTRUMENTE GMBH
      • 8.10.1.1. Overview
      • 8.10.1.2. Products & services
    • 8.10.2. APOLLO SURGICAL INDUSTRIES INC. (ASI)
      • 8.10.2.1. Overview
      • 8.10.2.2. Products & services
    • 8.10.3. ATRIUM MEDICAL CORPORATION
      • 8.10.3.1. Overview
      • 8.10.3.2. Financials
      • 8.10.3.3. Products & services
      • 8.10.3.4. Strategy
    • 8.10.4. DIMEDA SURGICAL INSTRUMENTS
      • 8.10.4.1. Overview
      • 8.10.4.2. Products & services
    • 8.10.5. INTUITIVE SURGICAL INC.
      • 8.10.5.1. Overview
      • 8.10.5.2. Financials
      • 8.10.5.3. Products & services
      • 8.10.5.4. Strategy
    • 8.10.6. SCANLAN INTERNATIONAL INC.
      • 8.10.6.1. Overview
      • 8.10.6.2. Primary business
      • 8.10.6.3. Products & services
    • 8.10.7. TELEFLEX INC.
      • 8.10.7.1. Overview
      • 8.10.7.2. Financials
      • 8.10.7.3. Products & services
      • 8.10.7.4. Strategy
    • 8.10.8. KARL STORZ GMBH & CO. KG
      • 8.10.8.1. Overview
      • 8.10.8.2. Financials
      • 8.10.8.3. Products & services
      • 8.10.8.4. Strategy
    • 8.10.9. TROKAMED GMBH
      • 8.10.9.1. Overview
      • 8.10.9.2. Products & services

LIST OF TABLES

  • TABLE 1. ASSUMPTIONS FOR PROCEDURES
  • TABLE 2. ASSUMPTIONS FOR DEVICES
  • TABLE 3. ASSUMPTIONS FOR MARKET SHARE
  • TABLE 4. GLOBAL NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 5. MOLECULAR TARGETED THERAPIES IN CLINICAL TRIALS
  • TABLE 6. NSCLC STAGE I & II: SURVIVAL RATES
  • TABLE 7. STAGE I NSCLC RESECTION: RECURRENCE RATES
  • TABLE 8. OUTCOME OF SURGICAL RESECTION
  • TABLE 9. SURGEONS: UNMET NEEDS
  • TABLE 10. PATIENTS & CAREGIVERS: UNMET NEEDS
  • TABLE 11. AIR LEAK SEALANTS
  • TABLE 12. INCIDENCE OF FAILURE DURING INFLATION
  • TABLE 13. END-USER SEGMENTS FOR LUNG CANCER SURGERIES
  • TABLE 14. PIPELINE PROCEDURES FOR LUNG CANCER SURGERY
  • TABLE 15. VATS VS OPEN SURGERY
  • TABLE 16. HOSPITAL STAY & COST COMPARISON OF OPEN SURGERY VS VATS VS ROBOTIC SURGERY
  • TABLE 17. GLOBAL NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 18. GLOBAL THORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 19. GLOBAL THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 20. GLOBAL VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 21. GLOBAL VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 22. ROBOTIC SURGERY: ADVANTAGES & DISADVANTAGES
  • TABLE 23. ROBOTIC PROCEDURES MARKET, BY GEOGRAPHY, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 24. ROBOTIC PROCEDURES MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
  • TABLE 25. OTHER PROCEDURES MARKET, BY GEOGRAPHY, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 26. OTHER PROCEDURES MARKET REVENUE, BY GEOGRAPHY, 2008 - 2015 ($MILLION)
  • TABLE 27. LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 28. LUNG CANCER SURGICAL DEVICES MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 29. LUNG CANCER SURGERY: HAND INSTRUMENTS MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($THOUSAND)
  • TABLE 30. LUNG CANCER SURGERY: POWERED DEVICES MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 31. LUNG CANCER SURGERY: MONITORING & VISUALIZATION SYSTEMS MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 32. LUNG CANCER SURGERY: ENDOSURGICAL EQUIPMENT MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 33. U.S: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 34. U.S: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 35. U.S: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 36. U.S: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 37. U.S: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 38. U.S: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 39. U.S: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 40. CANADA: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 41. CANADA: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 42. CANADA: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 43. CANADA: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 44. CANADA: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 45. CANADA: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 46. CANADA: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 47. UK: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 48. UK: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 49. UK: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 50. UK: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 51. UK: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 52. UK: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 53. UK: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 54. FRANCE: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 55. FRANCE: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 56. FRANCE: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 57. FRANCE: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 58. FRANCE: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 59. FRANCE: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 60. FRANCE: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 61. ITALY: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 62. ITALY: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 63. ITALY: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 64. ITALY: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 65. ITALY: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 66. ITALY: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 67. ITALY: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 68. SPAIN: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 69. SPAIN: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 70. SPAIN: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 71. SPAIN: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 72. SPAIN: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 73. SPAIN: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 74. SPAIN: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 75. GERMANY NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 76. GERMANY: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 77. GERMANY: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 78. GERMANY: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 79. GERMANY: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 80. GERMANY: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 81. GERMANY: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 82. ROE: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 83. ROE: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 84. ROE: THORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 85. ROE: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 86. ROE: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 87. ROE: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 88. ROE: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 89. ROW: NSCLC SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 90. ROW: NSCLC SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 91. ROW: THRORACOTOMY SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 92. ROW: THORACOTOMY SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 93. ROW: VATS SURGERY PROCEDURES, 2008 - 2015 (NO. OF PROCEDURES)
  • TABLE 94. ROW: VATS SURGERY PROCEDURES, BY REVENUE, 2008 - 2015 ($MILLION)
  • TABLE 95. ROW: LUNG CANCER SURGERY MARKET REVENUE, BY PRODUCTS, 2008 - 2015 ($MILLION)
  • TABLE 96. NEW PRODUCT LAUNCHES, 2008 - 2011
  • TABLE 97. AGREEMENTS & COLLABORATIONS, 2008 - 2010
  • TABLE 98. MERGERS & ACQUISITIONS
  • TABLE 99. APPROVALS, 2008 - 2011
  • TABLE 100. ACCURAY: TOTAL REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($THOUSAND)
  • TABLE 101. ACCURAY: CYBERKNIFE SYSTEM INSTALLATIONS, BY GEOGRAPHY, 2007 - 2010 (UNITS)
  • TABLE 102. ANGIODYNAMICS: TOTAL REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($THOUSAND)
  • TABLE 103. ANGIODYNAMICS: BUSINESS SEGMENT REVENUE, 2008 - 2010 ($THOUSAND)
  • TABLE 104. ANGIODYNAMICS: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($THOUSAND)
  • TABLE 105. BSD MEDICAL CORPORATION: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
  • TABLE 106. COVIDIEN: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
  • TABLE 107. COVIDIEN: REVENUE, BY SEGMENT, 2008 - 2010 ($MILLION)
  • TABLE 108. COVIDIEN: MEDICAL DEVICES SEGMENT REVENUE, 2008 - 2010 ($MILLION)
  • TABLE 109. COVIDIEN: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
  • TABLE 110. ETHICON ENDO-SURGERY (EES): REVENUE 2008 - 2010 ($MILLION)
  • TABLE 111. OLYMPUS CORPORATION: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
  • TABLE 112. OLYMPUS CORPORATION: REVENUE, BY SEGMENTS, 2008 - 2010 ($MILLION)
  • TABLE 113. OLYMPUS CORPORATION: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($MILLION)
  • TABLE 114. SIEMENS HEALTHCARE: REVENUE AND R&D EXPENDITURE, 2008 - 2010 ($MILLION)
  • TABLE 115. INTUITIVE SURGICAL: REVENUE AND R&D EXPENSES, 2007 - 2009 ($THOUSAND)
  • TABLE 116. TELEFLEX: REVENUE, BY SEGMENT, 2008 - 2010 ($THOUSAND)
  • TABLE 117. TELEFLEX: REVENUE, BY GEOGRAPHY, 2008 - 2010 ($THOUSAND)

LIST OFFIGURES

  • FIGURE 1. INNOVATIONS IN SURGICAL TREATMENT OF LUNG CANCER
  • FIGURE 2. LUNG CANCER OVERVIEW: A CHALLENGING DISEASE
  • FIGURE 3. LUNG CANCER: DISEASE CLASSIFICATION & TREATMENT MODES
  • FIGURE 4. LUNG CANCER: SURGERY MARKET SEGMENTATION
  • FIGURE 5. UNMET NEEDS IN LUNG CANCER SURGERY
  • FIGURE 6. MARKET SHARE ANALYSIS (2010)
  • FIGURE 7. LUNG CANCER: TREATMENT
  • FIGURE 8. LUNG CANCER SURGICAL INTERVENTION
  • FIGURE 9. SURGICAL PROCEDURES: DIAGRAMMATIC OVERVIEW 1
  • FIGURE 10. SURGICAL PROCEDURES: DIAGRAMMATIC OVERVIEW 2
  • FIGURE 11. CYBERKNIFE & ROBOTIC SURGERY
  • FIGURE 12. MARKET SEGMENTATION
  • FIGURE 13. MAJOR GROWTH STRATEGIES IN LUNG CANCER SURGERY MARKET (JANUARY 2008 - MARCH 2011)
Back to Top